{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:16:16Z","timestamp":1793042176241,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Special Training of Scientific and Technological Talents, China Academy of Chinese Medical Sciences","award":["ZZ13-YQ-028, ZZ13-YQ-023"],"award-info":[{"award-number":["ZZ13-YQ-028, ZZ13-YQ-023"]}]},{"name":"Fundamental Research Funds for the Central Public Welfare Research Institutes","award":["ZZ18-XRZ-028, ZZ17-XRZ-023"],"award-info":[{"award-number":["ZZ18-XRZ-028, ZZ17-XRZ-023"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82205226,82174465"],"award-info":[{"award-number":["82205226,82174465"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Beijing Municipality","award":["7232310"],"award-info":[{"award-number":["7232310"]}]},{"name":"Central High-level Hospital of Traditional Chinese Medicine Clinical Research and Achievement Transformation Capability Improvement Project","award":["HLCMHPP2023101"],"award-info":[{"award-number":["HLCMHPP2023101"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2024-2-4153"],"award-info":[{"award-number":["2024-2-4153"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have improved outcomes markedly over the past two decades. However, the vast majority of advanced NSCLCs become resistant to current treatments and eventually progress. A traditional Chinese medicine (TCM) formula of Shuangshen granules (SSG) has demonstrated potential in alleviating cancer side effects and improving survival rate. Despite clinical evidence supporting its benefit, there is still insufficient understanding of the active compounds in SSG and their underlying mechanisms, which limits its broader clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Lewis lung carcinoma (LLC) tumor-bearing mouse model was established to assess the efficacy of combined SSG and anti-PD-1 therapy in vivo, and myeloid-derived suppressor cells (MDSC) and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells were isolated for in vitro co-culture experiments, while pathological examination was conducted using hematoxylin and eosin (HE). The expression of PD-1, TIM-3, CTLA-4, LAG-3, Arg-1, IDO, iNOS, PD-L1 and Gal-9 was detected using immunohistochemistry (IHC), immunofluorescence, and flow cytometry and Western blotting. The expression of IL-2, TNF-\u03b1 and IFN-\u03b3 were detected by reverse transcription-quantitative polymerase chain reaction (qPCR). Concentrations of IL-10 and TGF-\u03b2 were measured by enzyme-linked immunosorbent assay (ELISA). Network pharmacology and molecular docking were utilized to screen for potential therapeutic targets and intervening signaling pathways of SSG in lung adenocarcinoma (LUAD). The predictions derived from this approach were further verified using Western blotting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In vivo experiments using LLC xenograft mice demonstrated that SSG suppressed tumor growth in a dose-dependent manner, with high-dose SSG showing optimal efficacy in inhibiting tumor angiogenesis and cell proliferation. SSG enhances anti-tumor immunity by reducing T cell exhaustion and MDSC-mediated immunosuppression, with SSG\u2009+\u2009anti-PD-1 combination therapy synergistically optimizing the tumor immune microenvironment. Network pharmacology analysis revealed 5 hub targets (IL2, STAT3, HSP90AA1, LGALS3, and FGF2) associated with immune, LUAD, and active ingredients of SSG, with significant enrichment in the PI3K-Akt pathway. Compared with the control group, the protein expression levels of p-PI3K and p-Akt in the SSG group were significantly down-regulated, indicating that the PI3K-Akt pathway may be inhibited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SSG could dose-dependently inhibit LLC tumor growth in mice and exert antitumor effects by alleviating T-cell exhaustion and MDSC-mediated immunosuppression. Notably, IL2, STAT3, HSP90AA1, LGALS3 and FGF2, as potential targets of SSG, were significantly enriched in the PI3K-Akt pathway, which provide a novel perspective for the treatment of LUAD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-026-01391-3","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:40:16Z","timestamp":1778049616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Shuangshen granules enhance anti-PD1 therapy effectiveness in lung adenocarcinoma by modulating myeloid-derived suppressor cell-induced T cell exhaustion"],"prefix":"10.1186","volume":"21","author":[{"given":"Zhong-ning","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-qi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-ling","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-lin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-lun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-zhi","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-jin","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"1391_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1391_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41423-020-00577-5","volume":"18","author":"F Zhou","year":"2021","unstructured":"Zhou F, Qiao M, Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol. 2021;18:279\u201393. https:\/\/doi.org\/10.1038\/s41423-020-00577-5.","journal-title":"Cell Mol Immunol"},{"key":"1391_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22:40. https:\/\/doi.org\/10.1186\/s12943-023-01740-y.","journal-title":"Mol Cancer"},{"key":"1391_CR4","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/jco.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, et al. Five-Year Overall Survival for Patients With Advanced Non\u2012Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019;37:2518\u201327. https:\/\/doi.org\/10.1200\/jco.19.00934.","journal-title":"J Clin Oncol"},{"key":"1391_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/cac2.12153","volume":"41","author":"J Kang","year":"2021","unstructured":"Kang J, Zhang C, Zhong WZ. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. Cancer Commun. 2021;41:287\u2013302. https:\/\/doi.org\/10.1002\/cac2.12153.","journal-title":"Cancer Commun"},{"key":"1391_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2022.09.005","volume":"86","author":"T Li","year":"2022","unstructured":"Li T, Qiao T. Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy. Semin Cancer Biol. 2022;86:117\u201325. https:\/\/doi.org\/10.1016\/j.semcancer.2022.09.005.","journal-title":"Semin Cancer Biol"},{"key":"1391_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663986","volume":"12","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Tang L, Zhou Y, He W, Li W. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. Front Immunol. 2021;12:663986. https:\/\/doi.org\/10.3389\/fimmu.2021.663986.","journal-title":"Front Immunol"},{"key":"1391_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399. https:\/\/doi.org\/10.1038\/nri3862.","journal-title":"Nat Rev Immunol"},{"key":"1391_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775\u201390. https:\/\/doi.org\/10.1038\/s41571-022-00689-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"1391_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21:184. https:\/\/doi.org\/10.1186\/s12943-022-01657-y.","journal-title":"Mol Cancer"},{"key":"1391_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/neuonc\/now287","volume":"19","author":"JP Antonios","year":"2017","unstructured":"Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1\/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017;19:796\u2013807. https:\/\/doi.org\/10.1093\/neuonc\/now287.","journal-title":"Neuro Oncol"},{"key":"1391_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/2326-6066.Cir-13-0016","volume":"1","author":"Y Pico de Coa\u00f1a","year":"2013","unstructured":"Pico de Coa\u00f1a Y, Poschke I, Gentilcore G, Mao Y, Nystr\u00f6m M, Hansson J, et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res. 2013;1:158\u201362. https:\/\/doi.org\/10.1158\/2326-6066.Cir-13-0016.","journal-title":"Cancer Immunol Res"},{"key":"1391_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00280-007-0571-z","volume":"62","author":"N Tomonaga","year":"2008","unstructured":"Tomonaga N, Nakamura Y, Soda H, Nagashima S, Nakano H, Kinoshita A, et al. Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2008;62:43\u20139. https:\/\/doi.org\/10.1007\/s00280-007-0571-z.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1391_CR14","first-page":"2","volume":"15","author":"YM Zhou","year":"2008","unstructured":"Zhou YM, Piao BK, Hou W, Lin HS, Hua BJ, Xiong L, et al. Clinical observation on Feiliuping Ointment improving immune status and prognosis in patients with non-small cell lung cancer. Chinese Journal of Information on Traditional Chinese Medicine. 2008;15:2.","journal-title":"Chinese Journal of Information on Traditional Chinese Medicine"},{"key":"1391_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1142\/s0192415x13500778","volume":"41","author":"YL Zhang","year":"2013","unstructured":"Zhang YL, Zhang R, Xu HL, Yu XF, Qu SC, Sui DY. 20(S)-protopanaxadiol triggers mitochondrial-mediated apoptosis in human lung adenocarcinoma A549 cells via inhibiting the PI3K\/Akt signaling pathway. Am J Chin Med. 2013;41:1137\u201352. https:\/\/doi.org\/10.1142\/s0192415x13500778.","journal-title":"Am J Chin Med"},{"key":"1391_CR16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1142\/s0192415x11009214","volume":"39","author":"PY Chou","year":"2011","unstructured":"Chou PY, Huang GJ, Pan CH, Chien YC, Chen YY, Wu CH, et al. Trilinolein inhibits proliferation of human non-small cell lung carcinoma A549 through the modulation of PI3K\/Akt pathway. Am J Chin Med. 2011;39:803\u201315. https:\/\/doi.org\/10.1142\/s0192415x11009214.","journal-title":"Am J Chin Med"},{"key":"1391_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/08820139.2025.2450246","volume":"54","author":"K Zhao","year":"2025","unstructured":"Zhao K, Ma Y, Luo J, Xu Y, Shou Q, Jiang H, et al. Hirsutella sinensis Fungus Promotes CD8(+) T Cell-Mediated Anti-Tumor Immunity by Affecting Tumor-Associated Macrophages-Derived CCRL2. Immunol Invest. 2025;54:573\u201388. https:\/\/doi.org\/10.1080\/08820139.2025.2450246.","journal-title":"Immunol Invest"},{"key":"1391_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.113305","volume":"281","author":"H Wei","year":"2021","unstructured":"Wei H, Guo C, Zhu R, Zhang C, Han N, Liu R, et al. Shuangshen granules attenuate lung metastasis by modulating bone marrow differentiation through mTOR signalling inhibition. J Ethnopharmacol. 2021;281:113305. https:\/\/doi.org\/10.1016\/j.jep.2020.113305.","journal-title":"J Ethnopharmacol"},{"key":"1391_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117590","volume":"322","author":"J Hu","year":"2024","unstructured":"Hu J, Jiang J, Xu B, Li Y, Wang B, He S, et al. Bioinformatics analyses of infiltrating immune cell participation on pancreatic ductal adenocarcinoma progression and in vivo experiment of the therapeutic effect of Shuangshen granules. J Ethnopharmacol. 2024;322:117590. https:\/\/doi.org\/10.1016\/j.jep.2023.117590.","journal-title":"J Ethnopharmacol"},{"key":"1391_CR20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41416-022-01800-y","volume":"127","author":"S Zhan","year":"2022","unstructured":"Zhan S, Lu L, Pan SS, Wei XQ, Miao RR, Liu XH, et al. Targeting NQO1\/GPX4-mediated ferroptosis by plumbagin suppresses in vitro and in vivo glioma growth. Br J Cancer. 2022;127:364\u201376. https:\/\/doi.org\/10.1038\/s41416-022-01800-y.","journal-title":"Br J Cancer"},{"key":"1391_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpba.2017.01.009","volume":"137","author":"QL Zhou","year":"2017","unstructured":"Zhou QL, Zhu DN, Yang YF, Xu W, Yang XW. Simultaneous quantification of twenty-one ginsenosides and their three aglycones in rat plasma by a developed UFLC-MS\/MS assay: Application to a pharmacokinetic study of red ginseng. J Pharm Biomed Anal. 2017;137:1\u201312. https:\/\/doi.org\/10.1016\/j.jpba.2017.01.009.","journal-title":"J Pharm Biomed Anal"},{"key":"1391_CR22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162\u201374. https:\/\/doi.org\/10.1038\/nri2506.","journal-title":"Nat Rev Immunol"},{"key":"1391_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106179","volume":"80","author":"X Song","year":"2020","unstructured":"Song X, Zhang Y, Dai E, Wang L, Du H. Prediction of triptolide targets in rheumatoid arthritis using network pharmacology and molecular docking. Int Immunopharmacol. 2020;80:106179. https:\/\/doi.org\/10.1016\/j.intimp.2019.106179.","journal-title":"Int Immunopharmacol"},{"key":"1391_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1039\/c4np00080c","volume":"32","author":"AS Wong","year":"2015","unstructured":"Wong AS, Che CM, Leung KW. Recent advances in ginseng as cancer therapeutics: a functional and mechanistic overview. Nat Prod Rep. 2015;32:256\u201372. https:\/\/doi.org\/10.1039\/c4np00080c.","journal-title":"Nat Prod Rep"},{"key":"1391_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25092068","volume":"25","author":"NH Yim","year":"2020","unstructured":"Yim NH, Kim YS, Chung HS. Inhibition of Programmed Death Receptor-1\/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites. Molecules. 2020;25:25092068. https:\/\/doi.org\/10.3390\/molecules25092068.","journal-title":"Molecules"},{"key":"1391_CR26","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/eji.202048534","volume":"50","author":"J Koh","year":"2020","unstructured":"Koh J, Kim Y, Lee KY, Hur JY, Kim MS, Kim B, et al. MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. Eur J Immunol. 2020;50:1810\u20139. https:\/\/doi.org\/10.1002\/eji.202048534.","journal-title":"Eur J Immunol"},{"key":"1391_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/1758835921992968","volume":"13","author":"J Qu","year":"2021","unstructured":"Qu J, Mei Q, Liu L, Cheng T, Wang P, Chen L, et al. The progress and challenge of anti-PD-1\/PD-L1 immunotherapy in treating non-small cell lung cancer. Ther Adv Med Oncol. 2021;13:1758835921992968. https:\/\/doi.org\/10.1177\/1758835921992968.","journal-title":"Ther Adv Med Oncol"},{"key":"1391_CR28","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1158\/0008-5472.Can-04-0465","volume":"64","author":"PC Rodriguez","year":"2004","unstructured":"Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64:5839\u201349. https:\/\/doi.org\/10.1158\/0008-5472.Can-04-0465.","journal-title":"Cancer Res"},{"key":"1391_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00398","volume":"9","author":"V Fleming","year":"2018","unstructured":"Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, et al. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. Front Immunol. 2018;9:398. https:\/\/doi.org\/10.3389\/fimmu.2018.00398.","journal-title":"Front Immunol"},{"key":"1391_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u201368. https:\/\/doi.org\/10.1038\/nri3175.","journal-title":"Nat Rev Immunol"},{"key":"1391_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1564505","volume":"8","author":"E Limagne","year":"2019","unstructured":"Limagne E, Richard C, Thibaudin M, Fumet JD, Truntzer C, Lagrange A, et al. Tim-3\/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology. 2019;8:e1564505. https:\/\/doi.org\/10.1080\/2162402x.2018.1564505.","journal-title":"Oncoimmunology"},{"key":"1391_CR32","doi-asserted-by":"publisher","unstructured":"Zhao Y, Wu T, Shao S, Shi B, Zhao Y. Phenotype, development, and biological function of myeloid-derived suppressor cells. Oncoimmunology 2016;5:e1004983. https:\/\/doi.org\/10.1080\/2162402x.2015.1004983","DOI":"10.1080\/2162402x.2015.1004983"},{"key":"1391_CR33","doi-asserted-by":"publisher","unstructured":"Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, et al. CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity 2016;44:303\u2013315. https:\/\/doi.org\/10.1016\/j.immuni.2016.01.014","DOI":"10.1016\/j.immuni.2016.01.014"},{"key":"1391_CR34","doi-asserted-by":"publisher","unstructured":"Miret JJ, Kirschmeier P, Koyama S, Zhu M, Li YY, Naito Y, et al. Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. J Immunother Cancer 2019;7:32. https:\/\/doi.org\/10.1186\/s40425-019-0504-5","DOI":"10.1186\/s40425-019-0504-5"},{"key":"1391_CR35","doi-asserted-by":"publisher","unstructured":"Jiang W, He Y, He W, Wu G, Zhou X, Sheng Q, et al. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. Front Immunol 2020;11:622509. https:\/\/doi.org\/10.3389\/fimmu.2020.622509","DOI":"10.3389\/fimmu.2020.622509"},{"key":"1391_CR36","doi-asserted-by":"publisher","unstructured":"Zhao F, Zhu G, He J, Xu X, Zhu W, Jiang W, et al. CircMAPK1 promoted CD8\u00a0+\u00a0T cell infiltration in LUAD by improving the IGF2BP1 dependent CCL5 upregulation. Int Immunopharmacol 2024;127:111267. https:\/\/doi.org\/10.1016\/j.intimp.2023.111267","DOI":"10.1016\/j.intimp.2023.111267"},{"key":"1391_CR37","doi-asserted-by":"publisher","unstructured":"Wei FN, Chen ZL, Yang HF, Han L, Ding HM, Deng SG, et al. Effect of Sanqi Oral Liquid on the expressions of CD4\u207a, CD8\u207a and CD68\u207a cells in 5\/6 nephrectomized rats with chronic renal failure. Chin J Integr Med 2013;19:589\u2013595. https:\/\/doi.org\/10.1007\/s11655-012-1233-5","DOI":"10.1007\/s11655-012-1233-5"},{"key":"1391_CR38","doi-asserted-by":"publisher","unstructured":"Zou F, Lu L, Liu J, Xia B, Zhang W, Hu Q, et al. Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. Nat Commun 2019;10:4109. https:\/\/doi.org\/10.1038\/s41467-019-11893-4","DOI":"10.1038\/s41467-019-11893-4"},{"key":"1391_CR39","doi-asserted-by":"publisher","unstructured":"Zhang W, Yu L, Xu C, Tang T, Cao J, Chen L, et al. PLEK2 activates the PI3K\/AKT signaling pathway to drive lung adenocarcinoma progression by upregulating SPC25. Cell Biol Int 2024;48:1285\u20131300. https:\/\/doi.org\/10.1002\/cbin.12197","DOI":"10.1002\/cbin.12197"},{"key":"1391_CR40","doi-asserted-by":"publisher","unstructured":"Shi H, Li K, Ni Y, Liang X, Zhao X. Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Front Cell Dev Biol 2021;9:707198. https:\/\/doi.org\/10.3389\/fcell.2021.707198","DOI":"10.3389\/fcell.2021.707198"},{"key":"1391_CR41","doi-asserted-by":"publisher","unstructured":"Zhang M, Wang L, Liu W, Wang T, De Sanctis F, Zhu L, et al. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K\/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. J Immunol Res 2022;2022:2253436. https:\/\/doi.org\/10.1155\/2022\/2253436","DOI":"10.1155\/2022\/2253436"},{"key":"1391_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198551","volume":"14","author":"W Tian","year":"2023","unstructured":"Tian W, Qin G, Jia M, Li W, Cai W, Wang H, et al. Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade. Front Immunol. 2023;14:1198551. https:\/\/doi.org\/10.3389\/fimmu.2023.1198551.","journal-title":"Front Immunol"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01391-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-026-01391-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01391-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:40:19Z","timestamp":1778049619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-026-01391-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1186\/s13020-026-01391-3","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Animal Ethics Committee of Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences (Approval No. IACUC-GAMH-2022\u2013011). and carried out in accordance with the institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}